- Home
- USGO vs STRO Comparison
USGO vs STRO Comparison
Compare USGO & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | USGO | STRO |
|---|---|---|
| Founded | 2015 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.7M | 94.9M |
| IPO Year | 2023 | 2018 |
Fundamental Metrics
Financial Performance| Metric | USGO | STRO |
|---|---|---|
| Price | $9.95 | $9.73 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 7 |
| Target Price | ★ $26.50 | $19.67 |
| AVG Volume (30 Days) | 36.6K | ★ 110.8K |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $105,646,000.00 |
| Revenue This Year | N/A | $62.61 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.26 | $5.23 |
| 52 Week High | $14.93 | $24.80 |
Technical Indicators
Market Signals| Indicator | USGO | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 46.90 | 88.38 |
| Support Level | $9.60 | $7.88 |
| Resistance Level | $10.40 | $9.38 |
| Average True Range (ATR) | 0.46 | 0.63 |
| MACD | 0.12 | 0.73 |
| Stochastic Oscillator | 59.26 | 97.12 |
Price Performance
Historical ComparisonAbout USGO U.S. GoldMining Inc.
US Goldmining Inc is a mineral exploration and development company. It is focused on the exploration and development of a project located in Alaska, USA. The company's sole property is Whistler Project which is a gold-copper exploration project located in the Yentna Mining District, approximately 170 km northwest of Anchorage, Alaska.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.